Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid (RNA) interference. Its approved products include ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis, AMVUTTRA for ATTR and hATTR amyloidosis, Leqvio for hypercholesterolemia, Qfitlia for hemophilia A or B, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. The company also has a robust pipeline with candidates in Phase 3 trials such as Nucresiran for ATTR amyloidosis, and earlier-stage programs targeting hypertension, myasthenia gravis, hepatitis D, metabolic diseases, Alzheimer's disease, and other conditions.

Alnylam Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ALNY. The company is headquartered in the United States and its shares are traded in US Dollars (USD). As a US-based company listed on a major US exchange, its financial reporting and stock price are denominated in USD, making it accessible to investors through US brokerage accounts.

Alnylam Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies like Alnylam focus on developing therapies using biological processes and systems, often involving genetic engineering or molecular biology. Alnylam specializes in RNA interference (RNAi) technology, which silences specific genes to treat diseases. This places it at the forefront of innovative therapeutic approaches for conditions such as amyloidosis, hemophilia, porphyria, and hypercholesterolemia.

Alnylam Pharmaceuticals is based in the United States and operates globally. The company discovers, develops, manufactures, and commercializes its therapeutics worldwide. Its approved products, such as ONPATTRO, AMVUTTRA, and Leqvio, are marketed internationally for conditions like hATTR amyloidosis and hypercholesterolemia. The company's pipeline includes programs targeting diseases prevalent across various regions, including Alzheimer's disease, Parkinson's disease, and hepatitis D, indicating a broad global focus in both developed and emerging markets.

Alnylam's commercial portfolio includes six approved therapies: ONPATTRO and AMVUTTRA for ATTR amyloidosis, Leqvio for hypercholesterolemia, Qfitlia for hemophilia A or B, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. Its late-stage pipeline features Nucresiran (Phase 3 for ATTR amyloidosis), Zilebesiran (hypertension), Cemdisiran (myasthenia gravis, paroxysmal nocturnal hemoglobinuria, geographic atrophy), and Elebsiran (hepatitis D). Early-stage programs target metabolic diseases (Rapirosiran for MASH, ALN-4324 for type 2 diabetes), neurological disorders (Mivelsiran for Alzheimer's, ALN-HTT02 for Huntington's), and other conditions like obesity (ALN-2232) and bleeding disorders (ALN-6400).